Alpharma of the USA has signed an agreement to acquire the genericoral solid-dose pharmaceutical businesses of Australia-headquarted FH Faulding from Mayne Nickless, once the latter has completed its purchase of Faulding's overall health care and pharmaceutical businesses.
Alpharma is to pay approximately $660 million in cash for the businesses, which include the operations of Purepac Pharmaceuticals and Faulding Laboratories in the USA. Revenues for these operations are around $200 million annually. Meantime, Israel's Teva Pharmaceutical Industries is to buy Faulding's injectables unit from Mayne Nickless.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze